Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propylthiouracil
Drug ID BADD_D01869
Description A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Indications and Usage Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
Marketing Status approved; investigational
ATC Code H03BA02
DrugBank ID DB00550
KEGG ID D00562
MeSH ID D011441
PubChem ID 657298
TTD Drug ID D00MIN
NDC Product Code 33342-314; 67253-651; 68084-964; 49452-6112; 20012-0001; 0228-2348; 70752-171; 59348-0013; 65319-1059
UNII 721M9407IY
Synonyms Propylthiouracil | 6-Propyl-2-Thiouracil | 6 Propyl 2 Thiouracil
Chemical Information
Molecular Formula C7H10N2OS
CAS Registry Number 51-52-5
SMILES CCCC1=CC(=O)NC(=S)N1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.004---
Musculoskeletal discomfort15.03.04.001---
Haemorrhage24.07.01.002---
Urine odour abnormal20.02.01.020---
Antineutrophil cytoplasmic antibody positive13.06.01.012---
Inflammation08.01.05.007; 10.02.01.0890.009404%-
Disease recurrence08.01.03.0500.014106%-
Salivary gland disorder07.06.02.001---
Pigmentation disorder23.05.03.001---
Renal impairment20.01.03.0100.018808%-
Bone marrow failure01.03.03.005--
Liver injury09.01.07.022; 12.01.17.012---
Organising pneumonia22.01.02.0080.014106%-
Low birth weight baby18.04.02.0030.014106%-
Traumatic liver injury09.01.08.010; 12.01.17.027---
Acute kidney injury20.01.03.0160.028212%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.014106%-
Granulomatosis with polyangiitis10.02.02.018; 20.05.01.013; 22.01.01.015; 24.12.04.0110.018808%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.009404%-
Multiple organ dysfunction syndrome08.01.03.0570.028212%
Cryoglobulinaemia10.04.04.013; 24.12.04.0070.014106%-
IgA nephropathy10.02.01.063; 20.05.01.0160.009404%-
Live birth18.08.02.0070.014106%-
Anti-neutrophil cytoplasmic antibody positive vasculitis10.02.02.023; 24.12.04.0020.206889%-
Iodine allergy10.01.01.0160.009404%-
Pulmonary renal syndrome10.04.04.017; 20.05.01.019; 22.01.01.0220.032914%-
Hypothyroidic goitre05.02.03.011; 14.11.01.0530.009404%-
Therapy non-responder08.06.01.0630.009404%-
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene